Current and emerging targets to treat neuropathic pain.
Butera
John A
JA
Chemical and Screening Sciences, Wyeth Research CN 8000, Princeton, New Jersey 08543, USA. buteraj@wyeth.com
D000818:Animals; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects; D051656:KCNQ Potassium Channels / Q000187:drug effects; D010146:Pain / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D026941:Sodium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D050916:TRPV Cation Channels / Q000187:drug effects
D015220:Calcium Channels; D051656:KCNQ Potassium Channels; D026902:Potassium Channel Blockers; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D026941:Sodium Channel Blockers; D050916:TRPV Cation Channels; C494484:TRPV1 receptor; C104077:metabotropic glutamate receptor type 1; C494035:voltage gated calcium channel subunit Ca alpha2delta-1, human